ArticleCureus2025
Association Between Tumor-Infiltrating Immune Cells and Early Recurrence in Ampulla of Vater Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Ampulla of Vater carcinoma (AVC) is a rare gastrointestinal malignancy with limited evidence from large-scale clinical studies. Although curative resection remains the standard treatment, early recurrence significantly worsens prognosis. Increasing attention has been paid to the tumor immune microenvironment, particularly immune checkpoint molecules, which influence tumor behavior. This study aimed to identify clinicopathological and immunological factors associated with early recurrence in AVC. Methods We retrospectively analyzed 42 patients who underwent curative resection for AVC at Nagasaki University Hospital between October 2005 and March 2022. Early recurrence was defined as tumor relapse within one year after surgery. Immunohistochemical staining was performed for tumor-infiltrating immune cells, including CD4, CD8, PD-1, PD-L1, Foxp3, and TIM3. Statistical analyses included Fisher's exact test, Mann-Whitney U test, and Kaplan-Meier survival analysis. Results Seven patients (16.7%) experienced early recurrence. Compared with the non-early recurrence group, the early-recurrence group had significantly higher preoperative CA19-9 levels (p = 0.009) and higher incidences of vascular invasion (p = 0.002), perineural invasion (p = 0.002), lymph node metastasis, and advanced Union for International Cancer Control (UICC) stage (≥ IIB; both p < 0.05). Immunohistochemically, the early-recurrence group showed significantly increased expression of CD4⁺ T cells, PD-1, and PD-L1 (p < 0.001, 0.004, and < 0.001, respectively), whereas CD8, Foxp3, and TIM3 expression did not differ significantly. Kaplan-Meier analysis demonstrated significantly poorer overall survival in the early-recurrence group (p < 0.001). Conclusion Early recurrence of AVC is strongly associated with aggressive pathological features and distinct immune profiles, including increased expression of CD4⁺ T cells, PD-1, and PD-L1. These findings suggest a potential association between the tumor immune microenvironment and early recurrence in AVC. However, the present results should be interpreted as exploratory and hypothesis-generating. Further large-scale studies are warranted to clarify the biological significance of these immune features and their potential therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.